IL18 and familial pancreatic carcinoma: In our study, a 1.5–1.9-fold reduction of IL-18 Bpa was observed in all patients post-VT1021 treatment, suggesting that plasmatic IL-18 Bpa could be a potential pharmacodynamic biomarker for VT1021 in patients with GBM and pancreatic cancer (Table 5).